Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.004--Not Available
Abscess11.01.08.0010.001332%Not Available
Acidosis14.01.03.0020.000533%
Acute abdomen07.01.06.0150.000533%Not Available
Acute febrile neutrophilic dermatosis01.02.01.006; 23.03.03.0330.003463%Not Available
Acute hepatic failure09.01.03.0010.000208%Not Available
Acute leukaemia01.10.02.001; 16.01.02.0010.000556%Not Available
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.000208%Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.023282%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.002664%Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.0050.001865%Not Available
Acute respiratory distress syndrome22.01.03.0010.000556%
Acute respiratory failure14.01.04.004; 22.02.06.0010.000417%Not Available
Adrenal insufficiency05.01.02.001; 14.11.01.0040.000139%
Ageusia07.14.03.003; 17.02.07.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.003--Not Available
Alveolar proteinosis22.01.02.0090.000208%Not Available
Alveolitis allergic10.01.03.008; 22.01.01.0020.000533%Not Available
Amyloidosis10.02.05.0010.000139%Not Available
Anaemia01.03.02.0010.043159%
Anal fissure07.03.01.0020.001066%
Anal fistula07.11.05.0020.000208%
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene